Echo Therapeutics Announces $3 Million... ( FRANKLIN Mass. Nov. 13 /- Echo Therap...)

Echo Therapeutics Announces $3 Million Financing

Date:11/13/2009

FRANKLIN, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has entered into definitive agreements with accredited and institutional investors to raise approximately $3 million through the sale of approximately 2.37 million shares of common stock at $1.25 per share through a private placement transaction. The transaction will include approximately 2.2 million common stock purchase warrants with an exercise price equal to $2.00 per share and a term of five years. Burnham Hill Partners, LLC acted as placement agent for the transaction.

"We are extremely pleased to have executed on this financing," stated Patrick Mooney, M.D., Echo's Chairman and Chief Executive Officer. "With this additional capital, we will have the finances to advance our Prelude SkinPrep and Symphony tCGM Systems toward commercialization, which we expect to occur next year."

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. There shall not be any sale of these securities in any jurisdiction in which such offering would be unlawful. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and is developing the Symphony tCGM System, a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospita
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Cornerstone Therapeutics Appoints General Counsel
2. Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%
3. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 5
4. Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice President, Business Development
5. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
6. Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split
7. Cell Therapeutics, Inc. Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009
8. Tibotec Therapeutics Recognizes National Latino AIDS Awareness Day With Information and Insights for the Latino Community
9. Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
10. Meeting highlights the role of molecular imaging biomarkers in clinical research and therapeutics
11. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients

Post Your Comments:

(Date:5/22/2012)... Philadelphia, Pa. (May 22, 2012) Potentially severe hypersensitivity ... autoimmune mechanism, resulting from the creation of drug-induced immunogens ... to a study published online by the journal ... International AIDS Society . AIDS is published ... of Wolters Kluwer Health . , The study ...

(Date:5/22/2012)... weight-loss products are the types of dietary supplements most ... new study. Liver injury from medication is the ... and herbal supplements -- which do not require a ... online -- are used by up to 40 percent ... side effects are not well-known. In this study, ...

(Date:5/22/2012)... (HealthDay News) -- New Mexico has the highest rate ... Jersey has the lowest rate, according to a new ... 100,000 people, while New Jersey,s is about 36 per ... about 58 per 100,000, according to the report released ... Wood Johnson Foundation. Injuries that result from accidents, ...

(Date:5/22/2012)... When thousands of psychiatrists attend their field,s largest annual ... into drug treatments report overwhelmingly on positive results. ... in the Journal of Clinical Psychopharmacology by ... Yale University, who analyzed the presentations given at two ... Of 278 studies presented at the 2009 and 2010 ...

(Date:5/22/2012)... ANTONIO (May 22, 2012) An international task force ... distress syndrome (ARDS), a disease first recognized during the ... trouble breathing. , The new definition includes a distinction ... that are less advanced, said Antonio Anzueto, M.D., of ... the ARDS Definition Task Force. The guidelines are based ...

Breaking Medicine News(10 mins):Health News:Reactions to HIV drug have autoimmune cause, reports AIDS journal 2 Health News:Reactions to HIV drug have autoimmune cause, reports AIDS journal 3 Health News:Body Building, Diet Supplements Linked to Liver Damage: Study 2 Health News:Injury-Linked Deaths Vary Widely Among States 2 Health News:Bias found in mental health drug research presented at major psychiatric meeting 2 Health News:Bias found in mental health drug research presented at major psychiatric meeting 3 Health News:Revised ARDS definition sets out levels of severity 2

[0] Reactions to HIV drug have autoimmune cause, reports AIDS journal [0] Body Building, Diet Supplements Linked to Liver Damage: Study [0] Injury-Linked Deaths Vary Widely Among States [0] Bias found in mental health drug research presented at major psychiatric meeting [0] Revised ARDS definition sets out levels of severity

... Will Teach an Innovative Educational Event on the Web....,Four part web-based ... then will be available on every major social networking site afterwards ... ... Integrative medicine pioneer, renowned psychiatrist and educator, James S. Gordon, M.D., ...

... Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ), ... cosmetic treatments, today announced financial,results for the third ... ended September 30, 2008 were $24.2 million, of ... royalty revenues, $1.0 million,were funded development revenues, and ...

... Suggests Hospitals Increasingly use IROS to address the Joint ... ... Healthcare Management,announced today the results of its annual Hospital Peer ... U.S. hospital professionals on their use of AllMed,s external,peer review ...

... to Eat Right, Move More and ... Milk Their Diets, ATLANTA, Oct. ... different fad diets -- which seem to go in and out of,fashion like ... Americans -- including 56 percent of Georgia,residents -- remain overweight or obese., ...

... 30 Triple-S,Management Corporation (NYSE: GTS ), the ... consolidated revenues for the three,months ended September 30, 2008. ... includes an after tax net loss of $5.4 million, ... losses on investments and,derivatives. Also, the Company,s Board of ...

... Inc. (Nasdaq: MBRK ), a pharmaceutical company ... scheduled,to announce its financial results for the third ... the market opens. At 9:00 a.m. (ET) on ... to review the,Company,s third quarter financial results., ...

Integrative Medicine Pioneer To Host Free Groundbreaking Web Series on a Natural Approach for Treating Depression Palomar Medical Reports Financial Results for Third Quarter 2008 AllMed Announces Annual Hospital Peer Review Survey Results Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results

(Date:5/22/2012)... CHICAGO, May 22, 2012 The hospitality industry ... with the season set to kickoff over the ... raising their hygiene standards – to the great ... UMF Corporation, a developer of infection prevention products. ... adopting environmental hygiene practices developed for the healthcare ...

(Date:5/22/2012)... Boehringer Ingelheim announced today results from ... compound tiotropium delivered once-daily via the Respimat ... moderate persistent asthma. The data were presented ... American Thoracic Society (ATS 2012). Boehringer Ingelheim ... trial program named UniTinA-asthma™ is ongoing to ...

(Date:5/22/2012)... 22, 2012 Medical Alarm Concepts Holding, Inc. ... from its largest ever set of orders for the ... technology, enabling the user to speak and listen directly ... the first tranche of this order resulted in revenue ... revenues from this same customer through the end of ...

Breaking Medicine Technology:With Busy Summer Forecast Ahead, More Hotels Are Raising Hygiene Standards, Says UMF Corporation 2 Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 2 Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 3 Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 4 Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial 2 Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial 3 The ARIA AE for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts AE for E Prescribing 16977 1 The ARIA AE for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts AE for E Prescribing 16977 2 The ARIA AE for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts AE for E Prescribing 16977 3 Dyadic International Reports 2011 First Quarter Financial Results 16975 1 Dyadic International Reports 2011 First Quarter Financial Results 16975 2 Dyadic International Reports 2011 First Quarter Financial Results 16975 3 Dyadic International Reports 2011 First Quarter Financial Results 16975 4 Dyadic International Reports 2011 First Quarter Financial Results 16975 5 Female to male transsexual people have more autistic traits 19131 1 Female to male transsexual people have more autistic traits 19131 2

[0] With Busy Summer Forecast Ahead, More Hotels Are Raising Hygiene Standards, Says UMF Corporation [0] Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma [0] Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial

... Calif., Dec. 2 TorreyPines Therapeutics, Inc. (Nasdaq: ... Phase II trial evaluating three doses of NGX267 as a ... syndrome. NGX267 met the primary endpoint of a statistically ... all three doses: 10 mg, 15 mg, and 20 mg. ...

... 2 A study has found that positron emission mammography ... affected by either breast density or a woman,s hormonal status, ... MRI at detecting cancer. Results will be presented today at ... (RSNA). , , "The ...

Other Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2 TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3 TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4 TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5 New Mammography Technology Effective in Detecting Breast Cancer 2 New Mammography Technology Effective in Detecting Breast Cancer 3 New Mammography Technology Effective in Detecting Breast Cancer 4

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia New Mammography Technology Effective in Detecting Breast Cancer

... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...

... Carl Zeiss is expanding the borders ... field, excellent color reproduction, high-contrast images ... patented optics provide improved resolution and ... (Systems Control Panel) combines all essential ...

Compact tray features all components for urethral catheterization....

Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....

Medicine Products:

Finnpipette Fixed Volume, 3000ul SteREO Discovery. V12 CURITY Urethral Catheter Tray (Open)Advance Plus Intermittent Catheter (Kit)

Echo Therapeutics Announces $3 Million...( FRANKLIN Mass. Nov. 13 /- Echo Therap...),Health